JP2011041578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011041578A5 JP2011041578A5 JP2010257738A JP2010257738A JP2011041578A5 JP 2011041578 A5 JP2011041578 A5 JP 2011041578A5 JP 2010257738 A JP2010257738 A JP 2010257738A JP 2010257738 A JP2010257738 A JP 2010257738A JP 2011041578 A5 JP2011041578 A5 JP 2011041578A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage unit
- expression vector
- alvac
- preparation according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50057203P | 2003-09-05 | 2003-09-05 | |
| US60/500,572 | 2003-09-05 | ||
| US50400703P | 2003-09-18 | 2003-09-18 | |
| US60/504,007 | 2003-09-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525474A Division JP2007503834A (ja) | 2003-09-05 | 2004-09-03 | 黒色腫用の多抗原ベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011041578A JP2011041578A (ja) | 2011-03-03 |
| JP2011041578A5 true JP2011041578A5 (enExample) | 2012-10-11 |
| JP5373747B2 JP5373747B2 (ja) | 2013-12-18 |
Family
ID=34316448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525474A Pending JP2007503834A (ja) | 2003-09-05 | 2004-09-03 | 黒色腫用の多抗原ベクター |
| JP2010257738A Expired - Fee Related JP5373747B2 (ja) | 2003-09-05 | 2010-11-18 | 黒色腫用の多抗原ベクター |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525474A Pending JP2007503834A (ja) | 2003-09-05 | 2004-09-03 | 黒色腫用の多抗原ベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8911991B2 (enExample) |
| EP (1) | EP1660119A2 (enExample) |
| JP (2) | JP2007503834A (enExample) |
| KR (1) | KR101141951B1 (enExample) |
| AU (2) | AU2004273034A1 (enExample) |
| BR (1) | BRPI0413334A (enExample) |
| CA (1) | CA2537931A1 (enExample) |
| IL (1) | IL173637A0 (enExample) |
| WO (1) | WO2005026370A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| EP1150710B1 (en) | 1999-02-17 | 2010-04-21 | Csl Limited | Immunogenic complexes and methods relating thereto |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| WO2005033278A2 (en) * | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| US20060217893A1 (en) * | 2005-01-07 | 2006-09-28 | Yanbin Li | Method for detecting an unknown contaminant concentration in a substance |
| WO2006120474A2 (en) * | 2005-05-13 | 2006-11-16 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against tumor antigens |
| WO2008028124A1 (en) * | 2006-09-01 | 2008-03-06 | The Board Of Trustees Of The University Of Arkansas | Methods and systems for detection of contaminants |
| WO2009042773A1 (en) * | 2007-09-25 | 2009-04-02 | University Of Miami | Adoptively transferred tumor-specific t cells stimulated ex vivo using herpes simplex virus amplicons |
| WO2011140284A2 (en) * | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| TWI733719B (zh) * | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
| US11564944B2 (en) | 2016-11-21 | 2023-01-31 | Nant Holdings Ip, Llc | Fractal combination therapy |
| WO2021101510A1 (en) | 2019-11-18 | 2021-05-27 | Google Llc | Privacy-aware meeting room transcription from audio-visual stream |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0789774A2 (en) * | 1994-10-03 | 1997-08-20 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
| US20030125536A1 (en) * | 1996-01-11 | 2003-07-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6770456B1 (en) * | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| EP1137792B9 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| WO2001030382A1 (en) * | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| EP1282702B1 (en) * | 2000-05-10 | 2006-11-29 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
| AU2001268452B2 (en) * | 2000-06-15 | 2006-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses |
| CA2429721A1 (en) * | 2000-11-28 | 2002-06-06 | Wyeth | Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| US20040091995A1 (en) * | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
| WO2003080800A2 (en) * | 2002-03-20 | 2003-10-02 | Aventis Pasteur, Inc. | Prevention and treatment of disease using angiogenesis-and/or tumor antigens |
| WO2003095642A2 (en) * | 2002-05-07 | 2003-11-20 | Aventis Pasteur, Ltd. | Polyepitopes and mini-genes for cancer treatment |
-
2004
- 2004-09-03 BR BRPI0413334-0A patent/BRPI0413334A/pt not_active IP Right Cessation
- 2004-09-03 KR KR1020067004548A patent/KR101141951B1/ko not_active Expired - Fee Related
- 2004-09-03 US US10/933,874 patent/US8911991B2/en not_active Expired - Fee Related
- 2004-09-03 EP EP04783109A patent/EP1660119A2/en not_active Ceased
- 2004-09-03 CA CA002537931A patent/CA2537931A1/en not_active Abandoned
- 2004-09-03 AU AU2004273034A patent/AU2004273034A1/en not_active Abandoned
- 2004-09-03 WO PCT/US2004/028751 patent/WO2005026370A2/en not_active Ceased
- 2004-09-03 JP JP2006525474A patent/JP2007503834A/ja active Pending
-
2006
- 2006-02-09 IL IL173637A patent/IL173637A0/en unknown
-
2010
- 2010-11-18 JP JP2010257738A patent/JP5373747B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-13 AU AU2011200127A patent/AU2011200127B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011041578A5 (enExample) | ||
| Zhang et al. | Biomaterials for vaccine-based cancer immunotherapy | |
| Elena Gomez et al. | Poxvirus vectors as HIV/AIDS vaccines in humans | |
| BR112015009320A2 (pt) | promotor pr13.5 para respostas de células t e anticorpo robustas | |
| ECSP17084137A (es) | Neoantígenos compartidos | |
| JP2012524075A5 (enExample) | ||
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| WO2010037395A3 (en) | Mhc multimers in cancer vaccines and immune monitoring | |
| BR112014026531A2 (pt) | proteínas de ligação de antígeno ligando cd30 humano | |
| MX377144B (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| JP2016516723A5 (enExample) | ||
| PE20081875A1 (es) | Procedimiento novedoso y composiciones | |
| JP2015529676A5 (enExample) | ||
| JP2016510989A5 (enExample) | ||
| JP2016074727A5 (enExample) | ||
| PH12018502403A1 (en) | Hiv vaccine formulation | |
| JP2015533376A5 (enExample) | ||
| Kim et al. | Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures | |
| JP2016508999A5 (enExample) | ||
| JP2010523138A5 (enExample) | ||
| AR053275A1 (es) | Composicion de vacuna | |
| JP2014533938A5 (enExample) | ||
| WO2017123976A8 (en) | Methods and compositions for influenza vaccination | |
| Dondji et al. | Intradermal NKT cell activation during DNA priming in heterologous prime‐boost vaccination enhances T cell responses and protection against Leishmania | |
| JP2014139185A5 (enExample) |